11 found
Order:
Disambiguations
Catherine Slack [9]Catherine M. Slack [1]Catherine May Slack [1]
  1.  70
    'It Looks Like You Just Want Them When Things Get Rough': Civil Society Perspectives on Negative Trial Results and Stakeholder Engagement in HIV Prevention Trials.Jennifer Koen, Zaynab Essack, Catherine Slack, Graham Lindegger & Peter A. Newman - 2012 - Developing World Bioethics 12 (3):138-148.
    Civil society organizations (CSOs) have significantly impacted on the politics of health research and the field of bioethics. In the global HIV epidemic, CSOs have served a pivotal stakeholder role. The dire need for development of new prevention technologies has raised critical challenges for the ethical engagement of community stakeholders in HIV research. This study explored the perspectives of CSO representatives involved in HIV prevention trials (HPTs) on the impact of premature trial closures on stakeholder engagement. Fourteen respondents from South (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  2.  59
    Stakeholder Perspectives on Ethical Challenges in Hiv Vaccine Trials in South Africa.Zaynab Essack, Jennifer Koen, Nicola Barsdorf, Catherine Slack, Michael Quayle, Cecilia Milford, Graham Lindegger, Chitra Ranchod & Richard Mukuka - 2010 - Developing World Bioethics 10 (1):11-21.
    There is little published literature on the ethical concerns of stakeholders in HIV vaccine trials. This study explored the ethical challenges identified by various stakeholders, through an open-ended, in-depth approach. While the few previous studies have been largely quantitative, respondents in this study had the opportunity to spontaneously identify the issues that they perceived to be of priority concern in the South African context. Stakeholders spontaneously identified the following as ethical priorities: informed consent, social harms, collaborative relationships between research stakeholders, (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  3.  51
    Enrolling Adolescents in HIV Vaccine Trials: Reflections on Legal Complexities From South Africa.Catherine Slack, Ann Strode, Theodore Fleischer, Glenda Gray & Chitra Ranchod - 2007 - BMC Medical Ethics 8 (1):1-8.
    Background South Africa is likely to be the first country in the world to host an adolescent HIV vaccine trial. Adolescents may be enrolled in late 2007. In the development and review of adolescent HIV vaccine trial protocols there are many complexities to consider, and much work to be done if these important trials are to become a reality. Discussion This article sets out essential requirements for the lawful conduct of adolescent research in South Africa including compliance with consent requirements, (...)
    Direct download (8 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  4.  22
    Defining and Negotiating the Social Value of Research in Public Health Facilities: Perceptions of Stakeholders in a Research‐Active Province of South Africa.Elizabeth Lutge, Catherine Slack & Douglas Wassenaar - 2017 - Bioethics 31 (2):128-135.
    This article reports on qualitative research conducted in KwaZulu-Natal, South Africa, among researchers and gate-keepers of health facilities in the province. Results suggest disparate but not irreconcilable perceptions of the social value of research in provincial health facilities. This study found that researchers tended to emphasize the contribution of research to the generation of knowledge and to the health of future patients while gate-keepers of health facilities tended to emphasize its contribution to the healthcare system and to current patients. Furthermore, (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  5.  26
    ‘It Looks Like You Just Want Them When Things Get Rough’: Civil Society Perspectives on Negative Trial Results and Stakeholder Engagement in HIV Prevention Trials.Jennifer Koen, Zaynab Essack, Catherine Slack, Graham Lindegger & Peter A. Newman - 2013 - Developing World Bioethics 13 (3):138-148.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  6.  17
    Stakeholder Views of Ethical Guidance Regarding Prevention and Care in HIV Vaccine Trials.Rika Moorhouse, Catherine Slack, Michael Quayle, Zaynab Essack & Graham Lindegger - 2014 - BMC Medical Ethics 15 (1):51.
    South Africa is a major hub of HIV prevention trials, with plans for a licensure trial to start in 2015. The appropriate standards of care and of prevention in HIV vaccine trials are complex and debated issues and ethical guidelines offer some direction. However, there has been limited empirical exploration of South African stakeholders’ perspectives on ethical guidance related to prevention and care in HIV vaccine trials.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  7.  30
    Treatment Needs in Hiv Prevention Trials: Using Beneficence to Clarify Sponsor-Investigator Responsibilities.Melissa Stobie & Catherine Slack - 2010 - Developing World Bioethics 10 (3):150-157.
    Some participants will get HIV-infected in HIV prevention trials, despite risk reduction measures. The subsequent treatment responsibilities of sponsor-investigators have been widely debated, especially where access to antiretroviral therapy (ART) is not available. In this paper, we explore two accounts of beneficence to establish whether they can shed light on sponsor-investigator responsibilities. We find the notion of general beneficence helpful insofar as it clarifies that some beneficent actions will be obligatory where they can be dispensed without scuppering the trial. We (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  8.  16
    Access to Treatment in Hiv Prevention Trials: Perspectives From a South African Community.Nicola Barsdorf, Suzanne Maman, Nancy Kass & Catherine Slack - 2010 - Developing World Bioethics 10 (2):78-87.
    Access to treatment, in HIV vaccine trials (HVTs), remains ethically controversial. In most prevention trials, including in South Africa, participants who seroconvert are referred to publicly funded programmes for treatment. This strategy is problematic when there is inadequate and uneven access to public sector antiretroviral therapy (ART) and support resources. The responsibilities, if any, of researchers, sponsors and public health authorities involved in HVTs has been hotly debated among academics, scholars, representatives of international organizations and sponsors. However, there is little (...)
    Direct download (9 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  9.  36
    Why We Don't Need a Relative Risk Standard for Adolescent HIV Vaccine Trials in South Africa.Catherine M. Slack - 2011 - American Journal of Bioethics 11 (6):21 - 22.
    The American Journal of Bioethics, Volume 11, Issue 6, Page 21-22, June 2011.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  10.  8
    Response to Hiv Vaccine Trials: Reconsidering the Therapeutic Misconception and the Question of What Constitutes Trial-Related Injuries.1.Catherine Slack & Melissa Stobie - 2008 - Developing World Bioethics 8 (2):159-161.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  11.  16
    Boni Mores and Consent for Child Research in South Africa.Ann Elaine Strode, Jacintha Toohey, Priya P. Singh & Catherine May Slack - 2015 - South African Journal of Bioethics and Law 8 (1):22.